BBOT Announces Multiple Presentations at the American Association for Cancer Research (AACR) Annual Meeting 2026
BridgeBio Oncology Therapeutics, Inc. (BBOT)
Company Research
Source: GlobeNewswire
SOUTH SAN FRANCISCO, Calif., March 18, 2026 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc. (“BBOT”) (Nasdaq: BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway malignancies, today announced multiple presentations at the American Association for Cancer Research (AACR) Annual Meeting 2026 being held on April 17-22, 2026, in San Diego, California. The abstracts released today can be found on the AACR website here. Details on the presentations are as follows: Title: The RAS: PI3Ka breaker BBO-10203 inhibits PI3Ka/AKT activity in HER2+ models through non-canonical RAS signaling blockadeSession Category: Experimental and Molecular TherapeuticsSession Title: Targeted Protein Degradation and Non-cannonical Oncogenic SignalingSession Type: Oral PresentationSession Date/Time: Tuesday, April 21, 2:30 p.m. – 4:30 p.m. PTLocation: Upper Level Ballroom 6DEAbstract Number: 6780 Presenter: James Stice, PhD, Director, BBOT Title: BBO-11818: an orally bioavai
Show less
Read more
Impact Snapshot
Event Time:
BBOT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BBOT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BBOT alerts
High impacting BridgeBio Oncology Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
BBOT
News
- BBOT Announces Publication in Cancer Discovery Highlighting Preclinical Data Demonstrating BBO-11818 is a Potent and Selective panKRAS InhibitorGlobeNewswire
- BridgeBio Oncology Therapeutics (BBOT) had its price target raised by HC Wainwright from $27.00 to $29.00. They now have a "buy" rating on the stock.MarketBeat
- BBOT Reports Fourth Quarter and Full Year 2025 Financial Results and Update on Corporate ProgressGlobeNewswire
- BBOT to Participate in Upcoming Investor Healthcare ConferencesGlobeNewswire
- BridgeBio Oncology Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire
BBOT
Earnings
- 3/5/26 - Beat
BBOT
Sec Filings
- 3/26/26 - Form 4
- 3/26/26 - Form 3
- 3/12/26 - Form 4
- BBOT's page on the SEC website